NVAX:NASDAQ
Novavax Inc
၁၂.၈၅ US$
arrow_upward
+၁.၆၆%(+၀.၂၁) 1D
အောက် ၁၅, GMT-၄ ၁၅:၅၆:၂၅ · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for NVAX...
Open
၁၂.၅၀ US$
High
၁၃.၂၅ US$
Low
၁၂.၁၈ US$
Mkt. cap
၂၁၂.၂၀ ဋေ
Avg. vol.
၇.၄၂ သန်း
Volume
၆.၂၀ သန်း
52-wk high
၁၃.၃၈ US$
52-wk low
၆.၂၀ US$
EPS
-၁.၅၂ US$
Beta
၂.၄၄
Shares outstanding
၁၆.၄၉ ကုဋေ
No. of employees
၇၄၉
Open
၁၂.၅၀ US$
High
၁၃.၂၅ US$
Low
၁၂.၁၈ US$
Mkt. cap
၂၁၂.၂၀ ဋေ
Avg. vol.
၇.၄၂ သန်း
Volume
၆.၂၀ သန်း
52-wk high
၁၃.၃၈ US$
52-wk low
၆.၂၀ US$
EPS
-၁.၅၂ US$
Beta
၂.၄၄
Shares outstanding
၁၆.၄၉ ကုဋေ
No. of employees
၇၄၉
News stories
From web sources and news partners
ad-hoc-news.de
·
ပြီးခဲ့သည့် ၁ နာရီ
BofA raises Novavax stock target from USD 7.00 to USD 8.00
GuruFocus
·
ပြီးခဲ့သည့် ၂ နာရီ
NVAX Maintained by Citigroup -- Price Target Raised to $8.00
Zacks
·
ပြီးခဲ့သည့် ၁ ရက်
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
News Corp
·
ပြီးခဲ့သည့် ၁ ရက်
Novavax Inc. stock outperforms competitors on strong trading day
Profile
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria.
Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine. Wikipedia
About Novavax Inc
CEOJohn C. Jacobs
Employees၇၄၉
Founded၁၉၈၇
HeadquartersGaithersburg, မေရီလန်းပြည်နယ်, ယူနိုက်တက်စတိတ်
Sector-
Websitenovavax.com